IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo

A potential anti-angiogenic therapeutic target

Tatiana Lobo, Luiza Coimbra Scalabrini, Leila da Silva Magalhães, Laura B. Cardeal, Felipe Silva Rodrigues, Edmilson Ozorio dos Santos, Albert S. Baldwin, Elena Levantini, Ricardo J. Giordano, Daniela Sanchez Bassères

Research output: Contribution to journalArticle

Abstract

Objectives: The ability of tumor cells to drive angiogenesis is an important cancer hallmark that positively correlates with metastatic potential and poor prognosis. Therefore, targeting angiogenesis is a rational therapeutic approach and dissecting proangiogenic pathways is important, particularly for malignancies driven by oncogenic KRAS, which are widespread and lack effective targeted therapies. Based on published studies showing that oncogenic RAS promotes angiogenesis by upregulating the proangiogenic NF-κB target genes IL-8 and VEGF, that NF-κB activation by KRAS requires the IKKβ kinase, and that targeting IKKβ reduces KRAS-induced lung tumor growth in vivo, but has limited effects on cell growth in vitro, we hypothesized that IKKβ targeting would reduce lung tumor growth by inhibiting KRAS-induced angiogenesis. Materials and methods: To test this hypothesis, we targeted IKKβ in KRAS-mutant lung cancer cell lines either by siRNA-mediated transfection or by treatment with Compound A (CmpdA), a highly specific IKKβ inhibitor, and used in vitro and in vivo assays to evaluate angiogenesis. Results and conclusions: Both pharmacological and siRNA-mediated IKKβ targeting in lung cells reduced expression and secretion of NF-κB-regulated proangiogenic factors IL-8 and VEGF. Moreover, conditioned media from IKKβ-targeted lung cells reduced human umbilical vein endothelial cell (HUVEC) migration, invasion and tube formation in vitro. Furthermore, siRNA-mediated IKKβ inhibition reduced xenograft tumor growth and vascularity in vivo. Finally, IKKβ inhibition also affects endothelial cell function in a cancer-independent manner, as IKKβ inhibition reduced pathological retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy.

Original languageEnglish
Pages (from-to)169-178
Number of pages10
JournalLung Cancer
Volume130
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Lung Neoplasms
Neoplasms
Lung
Small Interfering RNA
Therapeutics
Growth
Interleukin-8
Vascular Endothelial Growth Factor B
Pathologic Neovascularization
In Vitro Techniques
Human Umbilical Vein Endothelial Cells
Conditioned Culture Medium
Heterografts
Vascular Endothelial Growth Factor A
Cell Movement
Transfection
Carcinogenesis
Phosphotransferases
Endothelial Cells
Pharmacology

Keywords

  • Angiogenesis
  • IKKβ
  • IL-8
  • KRAS
  • Lung cancer
  • Therapeutic target
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Lobo, T., Scalabrini, L. C., Magalhães, L. D. S., Cardeal, L. B., Rodrigues, F. S., dos Santos, E. O., ... Bassères, D. S. (2019). IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target. Lung Cancer, 130, 169-178. https://doi.org/10.1016/j.lungcan.2019.02.027

IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo : A potential anti-angiogenic therapeutic target. / Lobo, Tatiana; Scalabrini, Luiza Coimbra; Magalhães, Leila da Silva; Cardeal, Laura B.; Rodrigues, Felipe Silva; dos Santos, Edmilson Ozorio; Baldwin, Albert S.; Levantini, Elena; Giordano, Ricardo J.; Bassères, Daniela Sanchez.

In: Lung Cancer, Vol. 130, 01.04.2019, p. 169-178.

Research output: Contribution to journalArticle

Lobo, T, Scalabrini, LC, Magalhães, LDS, Cardeal, LB, Rodrigues, FS, dos Santos, EO, Baldwin, AS, Levantini, E, Giordano, RJ & Bassères, DS 2019, 'IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target', Lung Cancer, vol. 130, pp. 169-178. https://doi.org/10.1016/j.lungcan.2019.02.027
Lobo, Tatiana ; Scalabrini, Luiza Coimbra ; Magalhães, Leila da Silva ; Cardeal, Laura B. ; Rodrigues, Felipe Silva ; dos Santos, Edmilson Ozorio ; Baldwin, Albert S. ; Levantini, Elena ; Giordano, Ricardo J. ; Bassères, Daniela Sanchez. / IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo : A potential anti-angiogenic therapeutic target. In: Lung Cancer. 2019 ; Vol. 130. pp. 169-178.
@article{8f5049716d92484d84dbe4d90bce6532,
title = "IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target",
abstract = "Objectives: The ability of tumor cells to drive angiogenesis is an important cancer hallmark that positively correlates with metastatic potential and poor prognosis. Therefore, targeting angiogenesis is a rational therapeutic approach and dissecting proangiogenic pathways is important, particularly for malignancies driven by oncogenic KRAS, which are widespread and lack effective targeted therapies. Based on published studies showing that oncogenic RAS promotes angiogenesis by upregulating the proangiogenic NF-κB target genes IL-8 and VEGF, that NF-κB activation by KRAS requires the IKKβ kinase, and that targeting IKKβ reduces KRAS-induced lung tumor growth in vivo, but has limited effects on cell growth in vitro, we hypothesized that IKKβ targeting would reduce lung tumor growth by inhibiting KRAS-induced angiogenesis. Materials and methods: To test this hypothesis, we targeted IKKβ in KRAS-mutant lung cancer cell lines either by siRNA-mediated transfection or by treatment with Compound A (CmpdA), a highly specific IKKβ inhibitor, and used in vitro and in vivo assays to evaluate angiogenesis. Results and conclusions: Both pharmacological and siRNA-mediated IKKβ targeting in lung cells reduced expression and secretion of NF-κB-regulated proangiogenic factors IL-8 and VEGF. Moreover, conditioned media from IKKβ-targeted lung cells reduced human umbilical vein endothelial cell (HUVEC) migration, invasion and tube formation in vitro. Furthermore, siRNA-mediated IKKβ inhibition reduced xenograft tumor growth and vascularity in vivo. Finally, IKKβ inhibition also affects endothelial cell function in a cancer-independent manner, as IKKβ inhibition reduced pathological retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy.",
keywords = "Angiogenesis, IKKβ, IL-8, KRAS, Lung cancer, Therapeutic target, VEGF",
author = "Tatiana Lobo and Scalabrini, {Luiza Coimbra} and Magalh{\~a}es, {Leila da Silva} and Cardeal, {Laura B.} and Rodrigues, {Felipe Silva} and {dos Santos}, {Edmilson Ozorio} and Baldwin, {Albert S.} and Elena Levantini and Giordano, {Ricardo J.} and Bass{\`e}res, {Daniela Sanchez}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.lungcan.2019.02.027",
language = "English",
volume = "130",
pages = "169--178",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo

T2 - A potential anti-angiogenic therapeutic target

AU - Lobo, Tatiana

AU - Scalabrini, Luiza Coimbra

AU - Magalhães, Leila da Silva

AU - Cardeal, Laura B.

AU - Rodrigues, Felipe Silva

AU - dos Santos, Edmilson Ozorio

AU - Baldwin, Albert S.

AU - Levantini, Elena

AU - Giordano, Ricardo J.

AU - Bassères, Daniela Sanchez

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objectives: The ability of tumor cells to drive angiogenesis is an important cancer hallmark that positively correlates with metastatic potential and poor prognosis. Therefore, targeting angiogenesis is a rational therapeutic approach and dissecting proangiogenic pathways is important, particularly for malignancies driven by oncogenic KRAS, which are widespread and lack effective targeted therapies. Based on published studies showing that oncogenic RAS promotes angiogenesis by upregulating the proangiogenic NF-κB target genes IL-8 and VEGF, that NF-κB activation by KRAS requires the IKKβ kinase, and that targeting IKKβ reduces KRAS-induced lung tumor growth in vivo, but has limited effects on cell growth in vitro, we hypothesized that IKKβ targeting would reduce lung tumor growth by inhibiting KRAS-induced angiogenesis. Materials and methods: To test this hypothesis, we targeted IKKβ in KRAS-mutant lung cancer cell lines either by siRNA-mediated transfection or by treatment with Compound A (CmpdA), a highly specific IKKβ inhibitor, and used in vitro and in vivo assays to evaluate angiogenesis. Results and conclusions: Both pharmacological and siRNA-mediated IKKβ targeting in lung cells reduced expression and secretion of NF-κB-regulated proangiogenic factors IL-8 and VEGF. Moreover, conditioned media from IKKβ-targeted lung cells reduced human umbilical vein endothelial cell (HUVEC) migration, invasion and tube formation in vitro. Furthermore, siRNA-mediated IKKβ inhibition reduced xenograft tumor growth and vascularity in vivo. Finally, IKKβ inhibition also affects endothelial cell function in a cancer-independent manner, as IKKβ inhibition reduced pathological retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy.

AB - Objectives: The ability of tumor cells to drive angiogenesis is an important cancer hallmark that positively correlates with metastatic potential and poor prognosis. Therefore, targeting angiogenesis is a rational therapeutic approach and dissecting proangiogenic pathways is important, particularly for malignancies driven by oncogenic KRAS, which are widespread and lack effective targeted therapies. Based on published studies showing that oncogenic RAS promotes angiogenesis by upregulating the proangiogenic NF-κB target genes IL-8 and VEGF, that NF-κB activation by KRAS requires the IKKβ kinase, and that targeting IKKβ reduces KRAS-induced lung tumor growth in vivo, but has limited effects on cell growth in vitro, we hypothesized that IKKβ targeting would reduce lung tumor growth by inhibiting KRAS-induced angiogenesis. Materials and methods: To test this hypothesis, we targeted IKKβ in KRAS-mutant lung cancer cell lines either by siRNA-mediated transfection or by treatment with Compound A (CmpdA), a highly specific IKKβ inhibitor, and used in vitro and in vivo assays to evaluate angiogenesis. Results and conclusions: Both pharmacological and siRNA-mediated IKKβ targeting in lung cells reduced expression and secretion of NF-κB-regulated proangiogenic factors IL-8 and VEGF. Moreover, conditioned media from IKKβ-targeted lung cells reduced human umbilical vein endothelial cell (HUVEC) migration, invasion and tube formation in vitro. Furthermore, siRNA-mediated IKKβ inhibition reduced xenograft tumor growth and vascularity in vivo. Finally, IKKβ inhibition also affects endothelial cell function in a cancer-independent manner, as IKKβ inhibition reduced pathological retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy.

KW - Angiogenesis

KW - IKKβ

KW - IL-8

KW - KRAS

KW - Lung cancer

KW - Therapeutic target

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85062235852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062235852&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2019.02.027

DO - 10.1016/j.lungcan.2019.02.027

M3 - Article

VL - 130

SP - 169

EP - 178

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -